The diagram provides a big picture view of the structure of CP2H and its anticipated flow of operations. At the top of the image, four categories of partners are identified: academia, industry, non-profit and government. They are supported by five pillars called platforms: platform 1 for virus vectors, vaccines and biotherapeutic innovations; platform 2 for small molecules, antimicrobials and antiviral therapeutics; platform 3 for scalable biomanufacturing innovations; platform 4 for diagnostics and clinical assays; and platform 5 for cross-cutting social sciences strategies.
At the bottom, five components are shown: the Ottawa Hospital鈥檚 Biotherapeutics Manufacturing Centre, McMaster University鈥檚 Robert E. Fitzhenry Vector Laboratory, uSaskatchewan鈥檚 Vaccine and Infectious Disease Organization (VIDO), uAlberta鈥檚 Alberta Cell Therapy Manufacturing (ACTM) and Dalhousie University鈥檚 Canadian Centre for Vaccinology (CCfV).
Those pillars are surrounded by arrows demonstrating the full operating cycle, starting at the top with health research, biomanufacturing and training, followed by new vaccines diagnostics and therapeutics, new startup companies, and clinical testing and commercial approval.